We hosted a webinar for the Association of the British Pharmaceutical Industry members earlier this month. 

In the session, we shared our ambitions and priorities for public involvement, diversity and transparency in research, and our plans to develop new guidance for clinical trials. This follows the publication of the government’s response to update the UK clinical trials regulations.  

We’re committed to developing effective guidance to support these changes, working with the Medicines and Healthcare products Regulatory Agency, patients and the public, and our research community. If you’re interested in getting involved in this work, you can register your interest on our website or contact us directly. 

We’re looking for people interested in and affected by long-term research to help us organise an in-person event. 

We’re holding the event jointly with Genomics England and Our Future Health to understand what is important to people involved in long-term research and what we need to consider if their ability to consent changes.  

Long-term research takes place over many years and is also known as longitudinal research.  

We were thrilled to support the UK Network of Experimental Cancer Medicine Centres (ECMC) at their annual networking meeting this week. 

During the event, we discussed our work with them to help set up cancer clinical trials more quickly. 

ECMC is made up of 17 adult and 12 paediatric centres who help ensure discoveries that are made in laboratories become treatments of the future. 

We recently recruited six new volunteers to our Confidentiality Advisory Group (CAG). 

New member Sarah Palmer-Edwards blogs about why she joined the CAG and how it adds value to her role as Head of Information Governance and Data Protection Officer at Barts Health NHS Trust.  

Last month, we held an event with 17 leading health and social care organisations to celebrate and build on our Shared Commitment to Public Involvement.    

Our Public Involvement Manager, Barbara Molony-Oates, blogs about why the event was a crucial and important first step towards developing bold and ambitious actions to drive this work forward.  

Data from the first six months of the National Contract Value Review (NCVR) shows that, on average, commercial studies are achieving study set-up milestones 95 days quicker. 

The NCVR is the UK’s standardised, national approach to costing and contracting for commercial contract research. 

It was launched in October 2022 and is led by NHS England in partnership with DHSC, NIHR Clinical Research Network, the HRA and the Devolved Administrations.